Eli Health Company Profile

Background

Overview

Eli Health, founded in 2019 and headquartered in Montreal, Quebec, is a healthcare technology company dedicated to enhancing women's lifelong health through continuous, at-home hormone monitoring. The company's mission is to empower women by providing real-time insights into their hormonal health, enabling informed decisions across various life stages. Eli Health's primary focus is on developing saliva-based hormone testing technology that offers daily hormonal data, addressing critical areas such as menopause, fertility, contraception, and endocrine conditions.

Key Strategic Focus

Core Objectives

• Continuous Hormone Monitoring: Developing user-friendly devices that allow women to monitor hormone fluctuations in real-time from the comfort of their homes.

• Data Accessibility: Bridging the gap in hormonal health data by providing continuous, personalized hormone profiles.

• Women's Health Empowerment: Enabling women to make informed health decisions by offering insights into hormonal changes throughout their lives.

Areas of Specialization

• Saliva-Based Testing: Utilizing saliva samples for hormone analysis, offering a non-invasive and convenient alternative to traditional blood tests.

• Digital Health Integration: Combining hardware and software solutions to deliver immediate results and actionable insights via a mobile application.

Key Technologies Utilized

• Microfluidics and Nanotechnology: Employing advanced technologies to detect minuscule hormone levels in saliva accurately.

• Artificial Intelligence: Implementing AI algorithms to interpret hormone data and provide personalized health recommendations.

Primary Markets Targeted

• Women's Health Sector: Focusing on individuals seeking to monitor and manage hormonal health related to fertility, menopause, and overall well-being.

• Healthcare Providers: Offering tools for clinicians to support patient care with continuous hormonal data.

Financials and Funding

Funding History

• Pre-Seed Round (2020): Raised 1.9 million CAD to initiate product development and early-stage research.

• Seed Round (April 2023): Secured 5 million CAD to advance product development, clinical validation, and regulatory approvals.

Notable Investors

• Muse Capital: Led the seed round, focusing on underserved markets, including women's health.

• RH Capital and Cake Ventures: Participated in the seed round, emphasizing investments in healthcare innovations.

• TELUS Pollinator Fund for Good, Garage Capital, Leva Capital: Contributed to the funding, supporting category-defining businesses and healthcare advancements.

Utilization of Capital

• Product Development: Finalizing the design and functionality of the at-home hormone monitoring device.

• Clinical Validation: Conducting studies to ensure the accuracy and reliability of the technology.

• Regulatory Approvals: Navigating the necessary regulatory pathways to bring the product to market.

Pipeline Development

Key Pipeline Candidates

• Saliva-Based Hormone Monitoring Device: A compact, user-friendly device designed for daily hormone level tracking through saliva samples.

Stages of Development

• Research and Development: Completed initial R&D phases, resulting in over a dozen patent-pending inventions.

• Clinical Validation: Undergoing clinical studies to validate the device's efficacy and accuracy.

• Regulatory Approval: Preparing for submissions to health authorities for market approval.

Target Conditions

• Menopause Management: Providing insights into hormonal changes during the menopausal transition.

• Fertility Tracking: Assisting women in understanding ovulation cycles and fertility windows.

• Contraceptive Monitoring: Offering data to support contraceptive choices and effectiveness.

• Endocrine Disorders: Monitoring hormone levels related to conditions such as polycystic ovary syndrome (PCOS).

Anticipated Milestones

• Product Launch: Expected following successful clinical validation and regulatory approvals.

• Market Expansion: Plans to introduce the product to international markets post-launch.

Technological Platform and Innovation

Proprietary Technologies

• Saliva-Based Hormone Detection: A patented method for measuring hormone levels in saliva, enabling non-invasive, real-time monitoring.

Significant Scientific Methods

• Microfluidic Assays: Utilizing microfluidic technology to analyze small saliva samples efficiently.

• AI-Driven Data Interpretation: Applying machine learning algorithms to interpret hormone data and provide personalized health insights.

Leadership Team

Executive Profiles

• Marina Pavlovic Rivas, Co-founder & CEO: A repeat founder with a background in data science and communications, passionate about empowering individuals with information.

• Thomas Cortina, Co-founder & CTO: Brings expertise in physics and engineering, focusing on developing the technological infrastructure of Eli Health.

Clinical Advisors

• Dr. Alicia Robbins: Double board-certified in Gynecology and Lifestyle Medicine, specializing in personalized care during midlife transitions.

• Dr. Fady Hannah-Shmouni: Board-certified endocrinologist and geneticist, focusing on precision medicine and longevity healthcare.

• Dr. Rhonda Zwingerman: Reproductive endocrinology and infertility specialist, co-founder of Twig Fertility, dedicated to modernizing fertility care.

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The women's health technology market is expanding, driven by increasing awareness and demand for personalized health solutions.

• Industry Trends: A shift towards at-home health monitoring and digital health integration is evident, with consumers seeking convenient and accessible health data.

Competitor Analysis

• Modern Fertility: